Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

May 24, 2019

UCSF doses first patient in triple combination clinical trial of OncoSec’s TAVO, Epacadostat and KEYTRUDA

OncoSec Medical, a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, announced that the first patient has been dosed in TRIFECTA, a triple combination clinical trial of OncoSec's TAVO, an IDO1 drug (epacadostat) and KEYTRUDA in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer.

UCSF doses first patient in triple combination clinical trial of OncoSec’s TAVO, Epacadostat and KEYTRUDA